Madrigal Pharmaceuticals (MDGL)
(Delayed Data from NSDQ)
$223.29 USD
-6.29 (-2.74%)
Updated May 28, 2024 04:00 PM ET
After-Market: $223.32 +0.03 (0.01%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Brokerage Reports
0 items in cart
Madrigal Pharmaceuticals, Inc. [MDGL]
Reports for Purchase
Showing records 21 - 40 ( 184 total )
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Drugs
4Q20 Recap; First Top-Line Data Readout From Two Phase 3 Resmetirom Trials By Year-End; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Drugs
3Q20 Recap: MAESTRO-NAFLD-1 Fully Enrolled; Interim Data at AASLD 2020; Raise PT to $184
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Drugs
Final Program for Our Fourth Annual Virtual NASH Investor Conference
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Drugs
MAESTRO-NAFLD-1 Over-Enrolled; Open Label Cohort Data by YE20; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Drugs
MRI-PDFF Predictability Sets up Importance of Interim Open-Label Data by YE20
Provider: Piper Sandler
Analyst: Research Department
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Drugs
We are updating coverage of our Healthcare sector to better allocate our research resources in
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Drugs
2Q Recap: Despite Mitigation Strategy, COVID-19 May Impact Timelines; Affirm Buy, Tweak PT to $165
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Drugs
Healthcare- Three Must Dial-In Calls Next Week:
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Drugs
1Q Recap: New CCO Signals Light at the End of the Phase 3 Tunnel; Reduce PT to $168
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Drugs
1Q20 - Mastering MAESTRO Phase 3 Beautifully - Must Read
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Drugs
NASH: Semaglutide Data Came in Underwhelmingly Below Street Expectation
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Drugs
NASH: Impact of Semaglutide GLP-1 NASH Data on NASH Stocks
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Drugs
Do Not Miss Our GLP-1 Call with Dr. Juan Frias Today at 12pm ET
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Drugs
Healthcare Do Not Miss Our GLP-1 Call with Dr. Juan Frias on May 1 at 12pm
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Drugs
Do Not Miss Our GLP-1 Call with Dr. Juan Frias on May 1 at 12pm ET
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Drugs
Do Not Miss Part 1 on Monday of Our 4-Part NASH COVID-19 Call Series
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Drugs
Steady as She Goes! MAESTRO Studies Navigate Rough Seas Without Protocol Changes
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E